AstraZeneca (AstraZeneca) Long-Term Debt

: $22,365 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

AstraZeneca's Long-Term Debt for the quarter that ended in Dec. 2023 was $22,365 Mil.

AstraZeneca's quarterly Long-Term Debt declined from Jun. 2023 ($24,329 Mil) to Sep. 2023 ($22,225 Mil) but then increased from Sep. 2023 ($22,225 Mil) to Dec. 2023 ($22,365 Mil).

AstraZeneca's annual Long-Term Debt declined from Dec. 2021 ($28,134 Mil) to Dec. 2022 ($22,965 Mil) and declined from Dec. 2022 ($22,965 Mil) to Dec. 2023 ($22,365 Mil).

AstraZeneca Long-Term Debt Historical Data

The historical data trend for AstraZeneca's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

15,730.00

17,505.00

28,134.00

22,965.00

22,365.00

AstraZeneca Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt																22,965.00	26,916.00	24,329.00	22,225.00	22,365.00

AstraZeneca (NAS:AZN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

AstraZeneca Long-Term Debt Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (AstraZeneca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.